Jouko Isojarvi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jouko Isojarvi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alan G. Wade
Patients Direct, 3 Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, UK.
1 shared publication - Alice Guiraud-Diawara
Health Economics and Epidemiology and Global Analytics, Lundbeck SAS, Quai du Président Roosevelt 37-45, 92445 Issy-les-Moulineaux, France
1 shared publication - Clément François
Lundbeck SAS, Issy-les-Moulineaux, France
1 shared publication - Céline Quelen
Health Economics and Epidemiology and Global Analytics, Lundbeck SAS, Quai du Président Roosevelt 37-45, 92445 Issy-les-Moulineaux, France
1 shared publication Deborah Lee
Lundbeck LLC Deerfield Illinois U.S.A.
1 shared publicationGuangbin Peng
Lundbeck LLC Deerfield Illinois U.S.A.
1 shared publication
Latest Publications
- Open Access
- 1 July 2016
- Published by Elsevier in Epilepsy Research
- Vol. 123, 68-74
Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study
- 1 July 2016
- Published by Elsevier in Epilepsy Research
- Vol. 123, 68-74
Open AccessClobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study
- Open Access
Clobazam‐treated patients with Lennox‐Gastaut syndrome experienced fewer seizure‐related injuries than placebo patients during trial OV‐1012
Drop seizures are especially problematic in patients with Lennox‐Gastaut syndrome (LGS) because of their potential for serious injury. In this post hoc analysis of phase 3 OV‐1012 data, a medical review was conducted of seizure‐related injuries based on Medical Dictionary for Regulatory Activities (MedDRA) preferred terms from all adverse event (AE) listings. Patients receiving clobazam experienced fewer seizure‐related injuries than those receiving placebo (8.9% all clobazam dosages vs. 27.1% placebo, p ≤ 0.05). Significant differences in the rates of seizure‐related injuries were observed for the medium‐ and high‐dosage clobazam treatment groups (4.8% and 10.2%, respectively, p ≤ 0.05). A total of 50 of 53 AEs considered seizure‐related were mild or moderate in intensity; 3 severe AEs occurred in the placebo group (fall, contusion, and jaw fracture). A single serious AE (jaw fracture, which required hospitalization and surgery) occurred in a placebo‐treated patient. Most injuries resolved by the end of the study. This analysis indicates that the reduction in drop‐seizure frequency achieved with clobazam provides a clinically meaningful benefit, a reduced likelihood of experiencing seizure‐related injuries.
Open AccessClobazam‐treated patients with Lennox‐Gastaut syndrome experienced fewer seizure‐related injuries than placebo patients during trial OV‐1012
Drop seizures are especially problematic in patients with Lennox‐Gastaut syndrome (LGS) because of their potential for serious injury. In this post hoc analysis of phase 3 OV‐1012 data, a medical review was conducted of seizure‐related injuries based on Medical Dictionary for Regulatory Activities (MedDRA) preferred terms from all adverse event (AE) listings. Patients receiving clobazam experienced fewer seizure‐related injuries than those receiving placebo (8.9% all clobazam dosages vs. 27.1% placebo, p ≤ 0.05). Significant differences in the rates of seizure‐related injuries were observed for the medium‐ and high‐dosage clobazam treatment groups (4.8% and 10.2%, respectively, p ≤ 0.05). A total of 50 of 53 AEs considered seizure‐related were mild or moderate in intensity; 3 severe AEs occurred in the placebo group (fall, contusion, and jaw fracture). A single serious AE (jaw fracture, which required hospitalization and surgery) occurred in a placebo‐treated patient. Most injuries resolved by the end of the study. This analysis indicates that the reduction in drop‐seizure frequency achieved with clobazam provides a clinically meaningful benefit, a reduced likelihood of experiencing seizure‐related injuries.